联邦制药(03933.HK) 公布,全资附属联邦生物科技(珠海横琴)自主研发的1类创新药UBT251注射液获美国药品监督管理局“FDA”许可,同意开展慢性肾脏病“CKD”适应症II期临床试验。此前,CKD适应症已获得中国国家药品监督管理局临床试验批准。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.